Praxis Precision Medicines, Inc.
PRAX
Price:
$59.38
Market Cap:
$1.05B
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epil...[Read more]
Industry
Biotechnology
IPO Date
2020-10-16
Stock Exchange
NASDAQ
Ticker
PRAX
The ROE as of September 2024 (TTM) for Praxis Precision Medicines, Inc. (PRAX) is -61.47%
According to Praxis Precision Medicines, Inc.’s latest financial reports and current stock price. The company's current ROE is -61.47%. This represents a change of 167.29% compared to the average of -23.00% of the last 4 quarters.
Praxis Precision Medicines, Inc. (PRAX) Historical ROE (quarterly & annually)
How has PRAX ROE performed in the past?
The mean historical ROE of Praxis Precision Medicines, Inc. over the last ten years is -135.70%. The current -61.47% ROE has changed -54.70% with respect to the historical average. Over the past ten years (40 quarters), PRAX's ROE was at its highest in in the June 2019 quarter at 0%. The ROE was at its lowest in in the June 2020 quarter at -82.01%.
Average
-135.70%
Median
-132.74%
Minimum
-279.97%
Maximum
-21.51%
Praxis Precision Medicines, Inc. (PRAX) ROE by Quarter and Year
Discovering the peaks and valleys of Praxis Precision Medicines, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 320.78%
Maximum Annual ROE = -21.51%
Minimum Annual Increase = -75.71%
Minimum Annual ROE = -279.97%
| Year | ROE | Change |
|---|---|---|
| 2023 | -176.95% | -36.80% |
| 2022 | -279.97% | 320.78% |
| 2021 | -66.54% | 209.38% |
| 2020 | -21.51% | -75.71% |
| 2019 | -88.53% | -51.02% |
Praxis Precision Medicines, Inc. (PRAX) Average ROE
How has PRAX ROE performed in the past?
The current ROE of Praxis Precision Medicines, Inc. (PRAX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-174.48%
5-year avg
-126.70%
10-year avg
-135.70%
Praxis Precision Medicines, Inc. (PRAX) ROE vs. Peers
How is PRAX’s ROE compared to its peers?
Praxis Precision Medicines, Inc.’s ROE is greater than Molecular Partners AG (-33.08%), greater than Mineralys Therapeutics, Inc. (-42.61%), greater than AN2 Therapeutics, Inc. (-54.72%), greater than Pharvaris N.V. (-36.89%), greater than PepGen Inc. (-62.74%), greater than Theseus Pharmaceuticals, Inc. (-24.51%), greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than Cullinan Oncology, Inc. (-28.37%), greater than Enliven Therapeutics, Inc. (-29.31%), greater than Immuneering Corporation (-66.03%), greater than Anebulo Pharmaceuticals, Inc. (-122.97%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than HCW Biologics Inc. (-385.90%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Crinetics Pharmaceuticals, Inc. (-62.63%), greater than Dyne Therapeutics, Inc. (-68.85%), greater than Revolution Medicines, Inc. (-34.57%),
| Company | ROE | Market cap |
|---|---|---|
| -33.08% | $160.66M | |
| -42.61% | $581.30M | |
| -54.72% | $31.63M | |
| -36.89% | $1.09B | |
| -62.74% | $301.78M | |
| -24.51% | $181.50M | |
| -21.96% | $77.79M | |
| -28.37% | $998.94M | |
| -29.31% | $1.03B | |
| -66.03% | $67.61M | |
| -122.97% | $51.87M | |
| -47.03% | $535.14M | |
| -385.90% | $22.69M | |
| -57.89% | $801.30M | |
| -28.01% | $1.79B | |
| -62.63% | $4.22B | |
| -68.85% | $3.45B | |
| -34.57% | $7.36B |
Build a custom stock screener for Praxis Precision Medicines, Inc. (PRAX) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Praxis Precision Medicines, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Praxis Precision Medicines, Inc. (PRAX) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Praxis Precision Medicines, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Praxis Precision Medicines, Inc.'s ROE?
How is the ROE calculated for Praxis Precision Medicines, Inc. (PRAX)?
What is the highest ROE for Praxis Precision Medicines, Inc. (PRAX)?
What is the 3-year average ROE for Praxis Precision Medicines, Inc. (PRAX)?
What is the 5-year average ROE for Praxis Precision Medicines, Inc. (PRAX)?
How does the current ROE for Praxis Precision Medicines, Inc. (PRAX) compare to its historical average?